Literature DB >> 25680703

Refining Measurement of Substance Use Disorders Among Women of Child-Bearing Age Using Hospital Records: The Development of the Explicit-Mention Substance Abuse Need for Treatment in Women (EMSANT-W) Algorithm.

Taletha Mae Derrington1,2, Judith Bernstein3, Candice Belanoff3, Howard J Cabral4, Hermik Babakhanlou-Chase5, Hafsatou Diop6, Stephen R Evans3, Milton Kotelchuck7.   

Abstract

Substance use disorder (SUD) in women of reproductive age is associated with adverse health consequences for both women and their offspring. US states need a feasible population-based, case-identification tool to generate better approximations of SUD prevalence, treatment use, and treatment outcomes among women. This article presents the development of the Explicit Mention Substance Abuse Need for Treatment in Women (EMSANT-W), a gender-tailored tool based upon existing International Classification of Diseases, 9th Edition, Clinical Modification diagnostic code-based groupers that can be applied to hospital administrative data. Gender-tailoring entailed the addition of codes related to infants, pregnancy, and prescription drug abuse, as well as the creation of inclusion/exclusion rules based on other conditions present in the diagnostic record. Among 1,728,027 women and associated infants who accessed hospital care from January 1, 2002 to December 31, 2008 in Massachusetts, EMSANT-W identified 103,059 women with probable SUD. EMSANT-W identified 4,116 women who were not identified by the widely used Clinical Classifications Software for Mental Health and Substance Abuse (CCS-MHSA) and did not capture 853 women identified by CCS-MHSA. Content and approach innovations in EMSANT-W address potential limitations of the Clinical Classifications Software, and create a methodologically sound, gender-tailored and feasible population-based tool for identifying women of reproductive age in need of further evaluation for SUD treatment. Rapid changes in health care service infrastructure, delivery systems and policies require tools such as the EMSANT-W that provide more precise identification methods for sub-populations and can serve as the foundation for analyses of treatment use and outcomes.

Entities:  

Keywords:  Diagnosis code grouper; Hospital discharge data; Prevalence; Substance abuse; Women

Mesh:

Year:  2015        PMID: 25680703      PMCID: PMC4802156          DOI: 10.1007/s10995-015-1730-1

Source DB:  PubMed          Journal:  Matern Child Health J        ISSN: 1092-7875


  30 in total

1.  Resource use of elderly emergency department patients with alcohol-related diagnoses.

Authors:  Shadi S Saleh; Steve E Szebenyi
Journal:  J Subst Abuse Treat       Date:  2005-12

2.  Use of record linkage to examine alcohol use in pregnancy.

Authors:  Lucy Burns; Richard P Mattick; Margaret Cooke
Journal:  Alcohol Clin Exp Res       Date:  2006-04       Impact factor: 3.455

Review 3.  Drugs of abuse in pregnancy.

Authors:  A Wright; J Walker
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2001-12       Impact factor: 5.237

4.  The use of record linkage to examine illicit drug use in pregnancy.

Authors:  Lucy Burns; Richard P Mattick; Margaret Cooke
Journal:  Addiction       Date:  2006-06       Impact factor: 6.526

5.  Punishing pregnant drug-using women: defying law, medicine, and common sense.

Authors:  Jeanne Flavin; Lynn M Paltrow
Journal:  J Addict Dis       Date:  2010-04

6.  How do Trends for Behavioral Health Inpatient Care Differ from Medical Inpatient Care in U.S. Community Hospitals?

Authors:  Yuhua Bao; Roland Sturm
Journal:  J Ment Health Policy Econ       Date:  2001-06-01

7.  Development of the drug-exposed infant identification algorithm (DEIIA) and its application to measuring part C early intervention referral and eligibility in Massachusetts, 1998-2005.

Authors:  Taletha Mae Derrington
Journal:  Matern Child Health J       Date:  2013-11

8.  Hospital use and associated costs of children aged zero-to-two years with craniofacial malformations in Massachusetts.

Authors:  Judith Weiss; Milton Kotelchuck; Scott D Grosse; Susan E Manning; Marlene Anderka; Diego F Wyszynski; Howard Cabral; Wanda Barfield; Raul Garcia; Emily Lu; Cathy Higgins
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2009-11

9.  Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment.

Authors:  Carlos A Hernandez-Avila; Bruce J Rounsaville; Henry R Kranzler
Journal:  Drug Alcohol Depend       Date:  2004-06-11       Impact factor: 4.492

Review 10.  The destructive capacity of drug abuse: an overview exploring the harmful potential of drug abuse both to the individual and to society.

Authors:  Thomas Peter Fox; Govind Oliver; Sophie Marie Ellis
Journal:  ISRN Addict       Date:  2013-07-16
View more
  4 in total

1.  The Prevalence and Impact of Substance Use Disorder and Treatment on Maternal Obstetric Experiences and Birth Outcomes Among Singleton Deliveries in Massachusetts.

Authors:  Milton Kotelchuck; Erika R Cheng; Candice Belanoff; Howard J Cabral; Hermik Babakhanlou-Chase; Taletha M Derrington; Hafsatou Diop; Stephen R Evans; Judith Bernstein
Journal:  Matern Child Health J       Date:  2017-04

2.  A national profile of substance use disorder among Medicaid enrollees on the autism spectrum or with intellectual disability.

Authors:  Anne M Roux; Sha Tao; Steven Marcus; Viktor Lushin; Lindsay L Shea
Journal:  Disabil Health J       Date:  2022-03-07       Impact factor: 4.615

3.  Follow-up after gestational diabetes: a fixable gap in women's preventive healthcare.

Authors:  Judith Apt Bernstein; Emily Quinn; Omid Ameli; Myrita Craig; Timothy Heeren; Aviva Lee-Parritz; Ronald Iverson; Brian Jack; Lois McCloskey
Journal:  BMJ Open Diabetes Res Care       Date:  2017-09-07

Review 4.  Automatable algorithms to identify nonmedical opioid use using electronic data: a systematic review.

Authors:  Chelsea Canan; Jennifer M Polinski; G Caleb Alexander; Mary K Kowal; Troyen A Brennan; William H Shrank
Journal:  J Am Med Inform Assoc       Date:  2017-11-01       Impact factor: 4.497

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.